Showing 3931-3940 of 8096 results for "".
- Platform Prints First Collagen-Based Bioink for Personalized Tissue Creationhttps://practicaldermatology.com/news/platform-prints-first-collagen-based-bioink-for-personalized-tissue-creation/2484559/Conexeu Sciences Inc. has announced the first 3D-printed tissue scaffolds created entirely from its proprietary extracellular matrix (ECM), according to a release from the manufacturer. Conexeu said their CXU™ platform, a bovin
- Trial for First Oral Minoxidil for Female Hair Loss Initiates Phase 3https://practicaldermatology.com/news/trial-for-first-oral-minoxidil-for-female-hair-loss-launches-phase-3/2484534/Veradermics, Inc. announced the initiation of patient enrollment in a phase 2/3 registration-directed clinical trial of VDPHL01, a novel extended-release oral minoxidil formulation, according to a press release. If approved, V
- Skin of Color Society Media Day Analyzes Latest Trendshttps://practicaldermatology.com/news/skin-of-color-society-media-day-analyzes-latest-trends/2484533/In an era of misinformation and viral skincare fads, the Skin of Color Society’s (SOCS) 8th Annual Media Day offered a timely and authoritative voice, gathering top board-certified dermatologists to address critical dermatologic topics relevant to patients with skin of color. From trending TikTok
- NIH Grants for Vitiligo Research Rise Over Time, Driven by Medical Schools and NIAMShttps://practicaldermatology.com/news/nih-grants-for-vitiligo-research-rise-over-time-driven-by-medical-schools-and-niams/2484513/Funding trends National Institutes of Health (NIH) funding trends shows steady, long-term support for vitiligo research from 1985 through 2024, according to a new analysis. Using the NIH Research Portfolio Online Reporting To
- Tralokinumab Maintains Efficacy in Hand AD Through 32 Weekshttps://practicaldermatology.com/news/tralokinumab-maintains-efficacy-in-hand-ad-through-32-weeks/2484484/LEO Pharma has announced positive 32-week topline results from its ADHAND trial, a phase 3b study evaluating tralokinumab in adults with moderate-to-severe atopic dermatitis (AD) with hand involvement. According to a press rele
- Novartis Launches Head-to-Head Trial of Remibrutinib vs Dupilumabhttps://practicaldermatology.com/news/novartis-launches-head-to-head-trial-of-remibrutinib-vs-dupilumab/2484430/Novartis, manufacturers of remibrutinib (Rhapsido), announced the launch of a US-based phase 3b clinical trial for the evaluation of early efficacy and safety of oral remibrutinib compared to injectable dupilumab in adults with chronic spontaneous urticaria (CSU) in
- FDA Warns Websites Selling Unapproved Botulinum Toxin Productshttps://practicaldermatology.com/news/fda-warns-websites-selling-unapproved-botulinum-toxin-products/2484341/The US Food and Drug Administration (FDA) has issued 18 warning letters to website operators illegally marketing unapproved and misbranded botulinum toxin products for cosmetic and medical use. The enforcement action follows reports of adverse events, including sym
- From ACAAI: Tapinarof Cream Shows Early Efficacy in Pediatric AD Regardless of Comorbiditieshttps://practicaldermatology.com/news/from-acaai-tapinarof-cream-shows-early-efficacy-in-pediatric-ad-regardless-of-comorbidities/2484383/New data from a pooled sub-analysis of the ADORING 1 and 2 trials show that VTAMA® (tapinarof) cream, 1%, was associated with improvements in children aged 2 to 17 with moderate to severe atopic dermatitis (AD). Results from th
- Pediatric AD: Tapinarof Cream 1% Delivers Clear Skin and Reduced Burdenhttps://practicaldermatology.com/news/pediatric-ad-tapinarof-cream-1-delivers-clear-skin-and-reduced-burden/2484254/In the pivotal ADORING 1 and 2 phase 3 trials, tapinarof cream 1% (VTAMA, Organon) showed consistent and statistically significant efficacy across all pediatric age groups in children with atopic dermatitis (AD), with benefits extending to sleep and family impact o
- BE HEARD: Bimekizumab Shows Sustained Relief in HS Symptoms Through 3 Yearshttps://practicaldermatology.com/news/be-heard-bimekizumab-shows-sustained-relief-in-hs-symptoms-through-3-years/2484274/Long-term data from the BE HEARD study showed BIMZELX® (bimekizumab-bkzx) was linked with sustained reductions in draining tunnels and clinically meaningful skin pain relief in patients with moderate-to-severe hidradenitis suppurativa (HS) through three years. <